Atossa Therapeutics Inc (ATOS) Quote

ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem

New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE

ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

Why the dump today? I was able to grab some at 1.65

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

ATOS new 52 hi

ATOS 10Q due 4/5

ATOS new 52 hi

ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

ATOS..LEVEL 2 LOOKING VERY NICE IN PRE

ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73

ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.

I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.

Looking good. Hidden gem not any longer

Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.

This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.

We are primed for a big run up people. In at 1.04

The market cap is less than their holdings in cash...clearly undervalued.

Insider buying by CEO and CFO, new patent protections...looking promising.

Yes. You likely lost a lot of money. This investment is worthless. RMSL

Did something just happen?

Looking for bottom here

Yes, very soon. This will reverse the trend.

Soon

Soon the 2.5's , 2.6's .....

Yes

The 2.6's on the horizon.

That's one of the things I like about them Also there should be some updates coming

140 millions of dollars cash? ATOS can do great things with this money.

Nice buy worth alot when this hits $10.00

Almost 36,000 shares buy at 2.49.

Good Old "Blue Sky Breakout"././//./..//.///.././..////

The Market is pulling it down with the broad sell-off. Will take some news like VSTM put out today to move up.

Down in pre-market, I guess not many people see it that way :-/

Atossa Therapeutics Is A Takeover Target Worth Triple It's Current Stock Price

https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5640574-atossa-therapeutics-is-takeover-target-worth-triple-current-stock-price

Big move coming, lots of buzz this weekend.

Press Release: Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
BY Dow Jones & Company, Inc.
— 5:22 PM ET 09/07/2021

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

Atossa establishes intended criteria for non-use of additional shares for financing transactions

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) , a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, has adjourned today's special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date.

The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote.

Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders vote in favor of the proposed increase in authorized shares.

The newly authorized shares of common stock are primarily intended to be used to complete and/or support acquisitions, collaborations, partnerships and licensing transactions. If the proposal is approved by the stockholders, Atossa does not intend to issue any of the newly authorized shares of common stock for the purpose of raising capital in the nine months following approval of the proposal at a price less than $10 per share.

Details of the proposal, the stockholder meeting, and additional information on how to vote your shares can be found in the proxy statement, available here: https://www.sec.gov/Archives/edgar/data/1488039/000143774921019134/atos20210809_ def14a.htm

Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.

About Atossa Therapeutics ( ATOS
Loading...
Loading...
)

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density, reduction of Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)

Kyle Guse, CFO and General Counsel

Office: (866) 893-4927

kyle.guse@atossainc.com

Investor Relations Contact:

Core IR

Office:(516) 222-2560

ir@atossainc.com

Source: Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)


Dow Jones Newswires
09-07-21 1722ET

What meeting?

This could go bigly up, or down after the the meeting!

October 1st $3.50 calls looking good @ .68 me thinks!

Still looking for the "missing link" here...

Yeah, mine is not so small.

No

Yeah. Small bet

Anyone else still in here ?